Business Wire

Metanoia Announces the Closing of a $19.3M New Round of Funding and Its Entry Into the 5G Market

Share

Metanoia Communications Inc. (Metanoia), a leading manufacturer of standalone high-speed xDSL and Gfast PHY chipsets for the wireline broadband market, is excited to announce that it has successfully completed its most significant fundraising in the history of the company from a stellar consortium of domestic investors led by Taiwania Capital Investment and National Development Fund. Elan Microelectronics, the original primary investor in Metanoia, is also participating in this new round of investment.

“Introduction of new and innovative products is a key area of focus in Metanoia’s strategy and this new round of investment will enable Metanoia to develop and release 5G chips for Remote Radio Units (RRU), Small Cells and CPEs in near future,” said Chien-Te Wu, Metanoia President & CEO. “The company will further capitalize on and broaden its established position as a recognized leader in the Broadband Wireline markets, where our employees are striving to enhance the overall customer experience, while deepening relationships with existing and new customers.”

Taiwania Capital CEO David Weng added: “Taiwania Capital Investment is very excited about investing in Metanoia as it embarks on a new journey with its strategic decision to diversify into the 5G market with the introduction of exciting new products with significant potential and market prospects.”

The funding will also be used to support the launch of Metanoia’s new Gfast / VDSL2 family of chipsets and is also expected to drive further international adoption and expansion.

5G solutions are rapidly moving beyond just providing indoor coverage within buildings or arenas, and are becoming strategic enablers of outdoor network densification for Services Providers and will be the key components in strengthening the Service Providers’ 5G deployments. Building chips that can serve both RRU and Small Cell markets as well as the CPE is an important element of Metanoia’s product strategy to meet these requirements.

“By developing our innovative and highly programmable architecture for our Broadband Wireline products, and by leveraging our partners’ knowledge in 5G technology, Metanoia quickly realized that it could adapt and use existing technology and apply it to certain 5G market segments,” added Didier Boivin, Metanoia executive vice president. “While the medium is different than what Metanoia has previously served, (wireless vs. wireline), there are significant overlaps at the physical layer (PHY) enabling Metanoia to leverage its existing technology and quickly come up with new 5G products and enable our current and future customers to meet the market requirements.”

“Taiwan is embarking on a strategy and plan for deploying 5G in both public and private enterprise networks in 2020. Key goals in Taiwan’s 5G program include providing end-end solutions in enterprise network for vertical applications and obtaining significant market shares for 5G related products,” said Dr. Li Fung Chang, CTO, 5G Technology Program Office, Ministry of Economic Affairs(MoEA). “To achieve these goals, it is counting on its domestic enterprises to contribute to the success of the program. Several companies are already enlisted from server companies to chipset companies like Metanoia. Upcoming new 5G products from Metanoia will bring the flexibility needed to implement features which could be helpful in quickly adapting to the changing market requirements and thereby creating lasting differentiators to the market.”

Metanoia will next participate at COMPUTEX 40th in Taipei, Taiwan from June 2nd to June 6th 2020.

Please come to visit us.

About Metanoia Communications, Inc.

Metanoia Communications, a subsidiary of Elan Microelectronics, was established in Hsinchu Science Park, Taiwan. Since its inception, Metanoia has been contributing to the development of several generations of semiconductor and software solutions for the wireline Broadband and the in-home networking markets, delivering to broadband manufacturers very high-speed PHY devices with reliable and superior performances.

For more information about Metanoia, please visit our website at www.metanoia-comm.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Metanoia Communications Inc.
Ting Liao
Email: sales@metanoia-comm.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release

Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release

ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye